MOLN

Molecular Partners (MOLN)

Molecular Partners AG

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MOLN

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/14	23 : 44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2024/06/14	14 : 00	GlobeNewswire Inc.	Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024	NASDAQ:MOLN	Molecular Partners AG
2024/06/11	23 : 16	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2024/06/11	14 : 00	GlobeNewswire Inc.	Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024	NASDAQ:MOLN	Molecular Partners AG
2024/06/04	06 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2024/06/01	21 : 00	GlobeNewswire Inc.	Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024	NASDAQ:MOLN	Molecular Partners AG
2024/05/17	19 : 25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
2024/05/17	19 : 25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
2024/05/17	19 : 25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
2024/05/17	19 : 25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
2024/05/17	05 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2024/05/17	05 : 00	GlobeNewswire Inc.	Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program	NASDAQ:MOLN	Molecular Partners AG
2024/04/30	00 : 00	GlobeNewswire Inc.	Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action	NASDAQ:MOLN	Molecular Partners AG
2024/04/20	00 : 12	GlobeNewswire Inc.	Life Science Cares Launches in Switzerland	NASDAQ:MOLN	Molecular Partners AG
2024/04/18	00 : 12	GlobeNewswire Inc.	Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	NASDAQ:MOLN	Molecular Partners AG
2024/03/26	22 : 26	GlobeNewswire Inc.	Molecular Partners Publishes Invitation to Annual General Meeting 2024	NASDAQ:MOLN	Molecular Partners AG
2024/03/15	05 : 00	GlobeNewswire Inc.	Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023	NASDAQ:MOLN	Molecular Partners AG
2024/03/02	06 : 00	GlobeNewswire Inc.	Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	NASDAQ:MOLN	Molecular Partners AG
2024/01/09	02 : 33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2024/01/08	06 : 00	GlobeNewswire Inc.	Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:MOLN	Molecular Partners AG
2024/01/06	06 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2024/01/06	06 : 00	GlobeNewswire Inc.	Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	NASDAQ:MOLN	Molecular Partners AG
2023/12/14	15 : 00	GlobeNewswire Inc.	Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences	NASDAQ:MOLN	Molecular Partners AG
2023/12/11	02 : 00	GlobeNewswire Inc.	Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
2023/11/14	15 : 00	GlobeNewswire Inc.	Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)	NASDAQ:MOLN	Molecular Partners AG
2023/11/04	01 : 00	GlobeNewswire Inc.	Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
2023/11/02	19 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
2023/11/02	15 : 00	GlobeNewswire Inc.	Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition	NASDAQ:MOLN	Molecular Partners AG
2023/11/01	15 : 00	GlobeNewswire Inc.	Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit	NASDAQ:MOLN	Molecular Partners AG
2023/10/27	05 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG